Rheumatoid arthritis following a treatment with IFN-alpha/ribavirin against HCV infection

Internal Medicine

Volumn 50, Issue 9, 2011, Pages 1065-1068

  Izumi, Yasumori ^a   Komori, Atsumasa ^a   Yasunaga, Yuki ^a   Hashimoto, Satoru ^a   Miyashita, Taiichiro ^a   Abiru, Seigo ^a   Yatsuhashi, Hiroshi ^a   Ishibashi, Hiromi ^a   Migita, Kiyoshi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Anti cyclic citrullinated peptide antibodies; B cell activating factor belonging to the TNF family (BAFF); Hepatitis C virus; Interferon; Rheumatoid arthritis; Ribavirin; Shared epitope

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; B CELL ACTIVATING FACTOR RECEPTOR; C REACTIVE PROTEIN; CREATININE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; HEMOGLOBIN; HLA DR ANTIGEN; METHOTREXATE; PEGINTERFERON ALPHA; RHEUMATOID FACTOR; RIBAVIRIN; SALAZOSULFAPYRIDINE; STROMELYSIN; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE EROSION; CASE REPORT; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; JOINT SWELLING; LABORATORY TEST; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; METACARPOPHALANGEAL JOINT; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYARTHRITIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SMOKING; WRIST;

ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; CYTOKINES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RIBAVIRIN; RISK FACTORS;

EID: 79955642668     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4790     Document Type: Article

References (21)

1. Ramos-Casals M, Muñoz S, Medina F, et al; HISPAMEC Study Group. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 36: 1442-1448, 2009.
2. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 32: 163-173, 2002.
3. Amati L, Caradonna L, Magrone T, et al. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin. Curr Pharm Des 8: 981-993, 2002.
4. Passos de Souza E, Evangelista Segundo PT, José FF, Lemaire D, Santiago M. Rheumatoid arthritis induced by alpha-interferon therapy. Clin Rheumatol 20: 297-299, 2001.
5. Sood A, Midha V, Sood N. Rheumatoid arthritis probably induced by pegylated interferon in a patient with chronic hepatitis C. Indian J Gastroenterol 23: 28-29, 2004.
6. Toubi E, Gordon S, Kessel A, et al. Elevated serum B-lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 27: 134-139, 2006.
7. Sène D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology 46: 65-69, 2007.
8. Zuckerman E, Keren D, Rozenbaum M, et al. Hepatitis C virusrelated arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 18: 579-584, 2000.
9. Koga T, Migita K, Miyashita T, et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol 26: 121-124, 2008.
10. van Gaalen FA, van Aken J, Huizinga TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50: 2113-2121, 2004.
11. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65: 3663-3671, 2006.
12. Majka DS, Deane KD, Parrish LA, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 67: 801-807, 2008.
13. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67: 212-217, 2008.
14. Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 40: 87-97, 2004.
15. Barnes E, Salio M, Cerundolo V, et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother 48: 3382-3389, 2004.
16. Kim HA, Jeon SH, Seo GY, Park JB, Kim PH. TGF-beta1 and IFN-gamma stimulate mouse macrophages to express BAFF via different signaling pathways. J Leukoc Biol 83: 1431-1439, 2008.
17. Liu Z, Bethunaickan R, Huang W, et al. Interferon alpha accelerates murine SLE in a T cell-dependent manner. Arthritis Rheum 63: 219-229, 2011.
18. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455-1463, 2008.
19. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 8: 243-265, 2005.
20. Bosello S, Youinou P, Daridon C, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35: 1256-1264, 2008.
21. Moura RA, Cascão R, Perpétuo I, et al. Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival. Rheumatology (Oxford) 50: 278-282, 2011.